Clinical Trials Logo

Stage III Malignant Mesothelioma clinical trials

View clinical trials related to Stage III Malignant Mesothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02106559 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy

Start date: September 4, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies photodynamic therapy during surgery in treating patients with pleural (the protective lining or membrane that covers the lungs and chest cavity) malignancy. Photodynamic therapy is an anti-cancer treatment that combines a photosensitizer (a substance that makes cells more sensitive to light), such as porfimer sodium, together with oxygen and visible light to kill tumor cells and/or damage the tumor's blood supply. Intraoperative (during surgery) photodynamic therapy may kill any tumor cells that remain after surgery.

NCT ID: NCT01503177 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This phase I clinical trial investigates the side effects and the best dose of local (intrapleural measles virus therapy in treating patients with malignant pleural mesothelioma (MPM). The investigators anticipate that the intrapleural of the vaccine strain measles virus will enable the virus to specifically infect and kill cancer cells and spare, without damaging normal cells. Furthermore, the investigators expect the measles virus to trigger an anti-tumor immune response which will result in additional destruction of the tumor by immune cells

NCT ID: NCT00107432 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.